Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA 2000 (Electroporation, EP)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs GLS 5300 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions
- Sponsors GeneOne Life Science
- 25 Jul 2019 According to an Inovio Pharmaceuticals media release, interim data from this trial is expected later in 2019.
- 25 Jul 2019 According to an Inovio Pharmaceuticals media release, based on the data from this study the company is planning a Phase 2 MERS vaccine trial to be conducted in areas of the world where outbreaks have occurred.
- 25 Mar 2019 Status changed from recruiting to active, no longer recruiting.